Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

(2016) Hossein-Ardeschir Ghofrani et al.   Lancet Respiratory Medicine

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

(2015) Lewis J. Rubin et al.   EUROPEAN RESPIRATORY JOURNAL

PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN RESPIRATORY JOURNAL

Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis

(2014) R S Baliga et al.   BRITISH JOURNAL OF PHARMACOLOGY

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natriuretic peptide metabolism, clearance and degradation

(2011) Lincoln R. Potter   FEBS Journal

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

(2009) N. Galie et al.   EUROPEAN HEART JOURNAL

Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension

(2008) Reshma S. Baliga et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE